From: Endoglin (CD105) and VEGF as potential angiogenic and dissemination markers for colorectal cancer
Characteristic | Patients (n = 93) | Frequency (%) |
---|---|---|
Gender | ||
Male | 58 | 62.4 |
Female | 35 | 37.6 |
Age (years) | ||
≤ 65 | 24 | 25.8 |
> 65 | 69 | 74.2 |
Tumor site | ||
Right colon | 31 | 33.3 |
Transverse colon | 8 | 8.6 |
Descending colon | 13 | 14 |
Sigmoid colon | 40 | 43 |
Synchronous tumors | 1 | 1.1 |
Colonoscopy biopsy | ||
Adenocarcinoma | 76 | 81.7 |
Polyp | 17 | 18.3 |
TNM postoperative stage (pTNM) | ||
Less aggressive (polyp, stages 0, I, and II) | 56 | 60.2 |
More aggressive (stages III and IV) | 37 | 39.8 |
Adjuvant treatment (XELOX, oxaliplatin-capecitabine) | ||
Yes | 42 | 45.2 |
No | 51 | 54.8 |
Metastasis | ||
Yes | 21 | 22.6 |
Synchronous | 12 | 12.9 |
Metachronous | 9 | 9.7 |
No | 72 | 77.4 |
Metastasis location | ||
Liver | 14 | 15.1 |
Lung | 2 | 2.1 |
Ganglion | 1 | 1.1 |
Other locations | 4 | 4.3 |
Survival (at the end of study) | ||
Alive | 88 | 94.6 |
Died | 5 | 5.4 |